Abstract: Filtration methods comprise virus-filtering a solution containing a least one macromolecule. In one embodiment, the total salt content of the solution is within the range of from about 0.2 M to 2 M. In another embodiment, the total salt content of the solution is within the range of from about 0.2 M up to saturation with a salt, and the salt is selected from the group consisting of sodium chloride, potassium chloride, sodium acetate, sodium citrate, sodium phosphate, potassium dyhydrophosphate and combinations thereof. In yet another embodiment, the total salt content of the solution is within the range of from about 0.2 M up to saturation with the salt and the macromolecule is in solution during the virus filtering.
Abstract: The present invention is directed to a novel Afx response element comprising the nucleotide sequence AACATGTT, said nucleotide sequence having a DNA binding site for the human fork head transkription factor Afx. The invention also relates to the use of the Afx response element in the screening for genes as diabetes drug targets and in the bioinformatic analysis of the human genome, said genes in turn being useful in other screening methods for compounds modifying the insulin receptor signaling pathway. A further aspect of the invention is a vector construct comprising the novel nucleotide sequence, a host cell transformed with said vector construct as well as the fusion protein expressed by said host cell.
Type:
Grant
Filed:
August 24, 2000
Date of Patent:
October 29, 2002
Assignee:
Biovitrum AB
Inventors:
Isabel Climent-Johansson, Karin Dahlman-Wright, Staffan Lake, Wyeth Wasserman
Abstract: Compounds of the general formula (I):
wherein the variables are as defined in the specification are useful for the prophylaxis or treatment of serotonin-related, especially 5-HT2 receptor-related, diseases in human beings or animals, particularly diseases related to the 5-HT2c receptor, especially diseases such as eating disorders, memory disorders, schizophrenia, mood disorders, anxiety disorders, pain, sexual dysfunctionions, and urinary disorders.
Type:
Grant
Filed:
June 8, 2000
Date of Patent:
October 15, 2002
Assignee:
Biovitrum AB
Inventors:
Björn Nilsson, Jan Tejbrant, Benjamin Pelcman, Erik Ringberg, Markus Thor, Jonas Nilsson, Mattias Jönsson
Abstract: The invention relates to the use of activated TRAP (tartrate-resistant and purple acid phosphatases) for screening for specific inhibitor of TRAP activity useful in the treatment of diseases or degenerative conditions resulting in increased bone resorption, such as tissue damages, bone metabolic disorders, osteoporosis. TRAP can be activated by proteolytic activation of TRAP e.g. by cleaving with a protease, papain-like enzyme.
Abstract: PROTEIN PURIFICATION I
The invention relates to processes for preparation of substantially pure antithrombin-III (AT-III), the antithrombin isoforms AT-III&agr; and AT-III&bgr;; and/or histidine-rich glycoprotein (HRGP). The processes comprise separating the said proteins on a cation exchange gel wherein the cation exchanger group is attached to the gel matrix via a linear polymer chain.
Abstract: A tissue treatment composition, especially an adhesive composition comprises (i) fibrin or fibrinogen and (ii) a biodegradable and biocompatible polymer capable of forming a viscous aqueous solution. In addition to glueing, the tissue adhesive composition may be used for slow-release of a drug incorporated into it or for anti-adherence purposes, for wound healing, etc.
Abstract: A crystalline form of mammalian TRAP (tartrate-resistant and purple acid phosphatase) is described. The enzyme is activated by cleavage prior to crystallization with a protease and the crystalline form of the mammalian TRAP is capable of being used for X-ray studies.
Abstract: Filtration methods comprise virus-filtering a solution containing at least one macromolecule. The total salt content of the solution is within the range of from about 0.2M to 2M or within the range of from about 0.2M up to saturation with the salt.
Abstract: The invention provides a method of treatment or prophylaxis of obesity, comprising administering to a patient in need of such treatment a therapeutically effective amount of an aryl sulfonamide compound of formula (I) or formula (II)
wherein the substituents are as described in the specification.
Type:
Grant
Filed:
July 20, 2001
Date of Patent:
June 4, 2002
Assignee:
Biovitrum AB
Inventors:
Patrizia Caldirola, Sukhwinder Jossan, Kjell S. Sakariassen, Jan Svartengren